REGN15505, Cemiplimab, REGN4336REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

Sponsor:

Regeneron Pharmaceuticals

Code:

NCT07594106

Conditions

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clear Cell Renal Cell Carcinoma (ccRCC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

REGN15505

REGN15505+Cemiplimab

REGN15505+REGN4336

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-02. This information was provided to ClinicalTrials.gov by Regeneron Pharmaceuticals on 2026-08-05.